Phase 2 RAS Clinical Trials
43 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 43 trials
Recruiting
Phase 2
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting
Phase 2
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Ras-mutated Metastatic Colorectal Cancer
Oncolytics Biotech60 enrolled1 locationNCT07446322
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1Phase 2
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT07537673
Recruiting
Phase 2
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University30 enrolled1 locationNCT07438106
Recruiting
Phase 1Phase 2
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Phase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 2
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled107 locationsNCT06368817
Recruiting
Phase 2
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 1Phase 2
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd442 enrolled52 locationsNCT05410145
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting
Phase 2
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Central Nervous System Nongerminomatous Germ Cell TumorChoriocarcinomaEmbryonal Carcinoma+7 more
Children's Oncology Group160 enrolled165 locationsNCT04684368
Recruiting
Phase 1Phase 2
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Advanced Solid CancerKRAS G12D Mutation
Arvinas Inc.159 enrolled14 locationsNCT07023731
Recruiting
Phase 1Phase 2
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
EGFR Inhibitor-associated Rash
Azitra Inc.32 enrolled6 locationsNCT06830863
Recruiting
Phase 1Phase 2
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 2
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic Ductal Adenocarcinoma (PDAC)KRAS G12D Mutations
Ranok Therapeutics (Hangzhou) Co., Ltd.60 enrolled2 locationsNCT07303465